Insulet Corp. soared as the Bedford company posted quarterly results. Revenue increased 20 percent to $57.4 million from a year earlier, and gross profit was up 24 percent to $25.2 million. Those increases, the company said, were driven by sales of the new, smaller, and lighter OmniPod Insulin Management System for diabetics, launched in the United States in February. Insulet’s net loss was $10.7 million, or $0.20 per share, compared to a net loss of $14.8 million, or $0.31, a year earlier.
Insulet boosts sales, narrows its net loss
You have reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week